{
    "Project Title": "An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma",
    "Sponsor": "Regeneron Pharmaceuticals, Inc.",
    "Study Number": "R2810-ONC-1676/GOG-3016 (CVP1601) ENGOT-cx9",
    "Protocol Version and Date": "R2810-ONC-1676/GOG-3016 (CVP1601) ENGOT cx9 Amendment 7",
    "Study Title": "An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma",
    "Phase": "Phase 3",
    "Therapeutic Area": "Oncology",
    "Number of Patients": "Approximately 590 patients projected (460 SCC patients)",
    "Number of Sites": "Approximately 100 sites globally",
    "Indication": "Recurrent or metastatic cervical carcinoma that has progressed after platinum-containing chemotherapy",
    "Duration of Treatment": "Not Available",
    "Schedule of Assessments": "Table 1: Schedule of Events: Screening and Treatment Period",
    "questionnaires": [
        {
            "longName": "EORTC QLQ-C30",
            "shortName": "EORTC QLQ-C30",
            "type": "PRO",
            "questionnaireSchedule": "Administered during clinic visits prior to any study procedures.",
            "questionnaireTiming": [
                "Study Procedure: Screening Visit X",
                "Study Procedure: Day 1   (Cycles 1 through 16 (cycle length = 6 weeks)  )",
                "Study Procedure: Follow-up Visits 1 and 21"
            ]
        }
    ]
}